LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

NCT07737925 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer

Interventions

DRUG: Xaluritamig

Sponsor

Thomas Jefferson University

Collaborators

[object Object]
[object Object]